Metagenomi Technologies, LLC

Emeryville, CA · Founded 2018 · Biotech · Public

In vivo genome editing platform for curative genetic medicines

Claim this profile

Follows are private to you and power your alerts

Updated · metagenomi.co

Sector
Biotech
Headquarters
Emeryville, CA
Founded
2018
Latest Form D
$95.8M, Jan 2023
Total capital
$345M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$345M
5 Form D · last Jan 2023
45 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

20192020202120222023FEDERAL ↑EQUITY ↓Cumulative $345M1st Form D$26.4M2nd Form D$37.5M3rd Form D$10M4th Form D$175M5th Form D$95.8M
20192020202120222023FEDERAL ↑EQUITY ↓Cumulative $345M2nd Form D$37.5M5th Form D$95.8M

Latest events

  • Private capital raisedForm D · SEC · 5th filing$95.8M
  • Private capital raisedForm D · SEC · 4th filing$175M
  • Private capital raisedForm D · SEC · 3rd filing$10M
  • Private capital raisedForm D · SEC · 2nd filing$37.5M
  • Private capital raisedForm D · SEC · 1st filing$26.4M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Founders and team

From SEC Form D filings
  • Andrew FarquharsonDirectorNamed in SEC Form D filings
  • Andrew LevinDirectorNamed in SEC Form D filings
  • Brian ThomasExecutive Officer, Director, PromoterNamed in SEC Form D filings
  • Jak KnowlesDirectorNamed in SEC Form D filings
  • Juergen EckhardtDirectorNamed in SEC Form D filings
  • Risa StackDirectorNamed in SEC Form D filings
Show all 10 people
  • Santhosh C. PalaniDirectorNamed in SEC Form D filings
  • Santosh PalaniDirectorNamed in SEC Form D filings
  • Sebastian C. BernalesDirectorNamed in SEC Form D filings
  • Willard C. DereDirectorNamed in SEC Form D filings

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

  • ImvaxSimilar federal contract value in Biotech · null in contracts
  • Zenas BioPharmaSimilar federal contract value in Biotech · null in contracts
  • ProEncia Biotechnology Inc.Similar federal contract value in Biotech · null in contracts
  • Harmony Biosciences II, Inc.Similar federal contract value in Biotech · null in contracts
  • Dewpoint TherapeuticsSimilar federal contract value in Biotech · null in contracts
  • Neurona TherapeuticsSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .